Table 10. Ames Test Results.

compd	dose (μg/plate)	no. of revertants without S9	no. of revertants in the presence of S9
3	15	5.5 ± 2.5	8.0 ± 0.5
	5	9.5 ± 0.5	6.0 ± 1.0
	1.6	8.5 ± 0.5	9.0 ± 0.5
	0.5	9.5 ± 0.5	9.0 ± 2.0
	0.18	9.0 ± 1.0	9.0 ± 0.5
7	20	8.5 ± 0.5	10.0 ± 0.5
	6	8.0 ± 0.5	9.0 ± 1.0
	2	11.5 ± 1.5	13.0 ± 2.0
	0.7	12.0 ± 1.0	12.5 ± 3.5
	0.2	12.0 ± 3.0	10.5 ± 0.5
9	20	4.0 ± 0.5	9.5 ± 3.5
	6.7	10.5 ± 2.0	14.5 ± 0.5
	2.2	7.5 ± 2.0	6.5 ± 0.5
	0.7	13.0 ± 9.0	8.5 ± 0.5
	0.27	8.5 ± 1.5	7.5 ± 1.5
14	20	(a)	5.0 ± 1.0
	6.7	9.5 ± 0.5	7.0 ± 0.5
	2.2	9.5 ± 3.0	7.0 ± 0.5
	0.7	2.5 ± 0.5	7.0 ± 3.0
	0.27	8.0 ± 1.0	7.5 ± 0.5
15	20	6.0 ± 3.0	11.5 ± 2.0
	6.7	25.0 ± 20.0	6.0 ± 0.5
	2.2	8.0 ± 1.5	9.0 ± 2.0
	0.7	10.5 ± 2.0	10.5 ± 0.5
	0.27	8.0 ± 4.0	9.5 ± 2.5
control (−) PBS	–	11.5 ± 2.5
control (+) NPDb	–	852	–
control (−) S9	–	–	9.5 ± 1.5
control (+) 2AFc	–	–	412

^aSome toxicity was observed that did not allow us to evaluate the revertants.

^bNPD (2-nitro-o-phenylendiamine).

^c2AF (2-aminofluorene).